Researchers at Valisure and Stanford University published a paper in The American Journal of Managed Care (AJMC) titled, Safety vs Price in the Generic Drug Market: Metformin. The paper concluded that recalls of metformin ER medications were effective in lowering NDMA levels below the FDA threshold; however, some samples of generic metformin still contained carcinogens even after recalls. The absence of any correlation of contamination levels with price indicates that potentially safer products are available on the market for the same price as poorer-quality products.

Researchers at Valisure and Stanford University published a paper in The American Journal of Managed Care (AJMC) titled, Safety vs Price in the Generic Drug Market: Metformin. The paper concluded that recalls of metformin ER medications were effective in lowering NDMA levels below the FDA threshold; however, some samples of generic metformin still contained carcinogens even after recalls. The absence of any correlation of contamination levels with price indicates that potentially safer products are available on the market for the same price as poorer-quality products.